Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients With Recurrent/Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00255788
• Other study ID #: I163
• Secondary ID: CAN-NCIC-IND163N
• Status: Completed
• Phase: Phase 2
• Start date: May 10, 2005
• Est. completion date: January 18, 2011

Study information

• Verified date: April 2020
• Source: Canadian Cancer Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor.

PURPOSE: This randomized phase II trial is studying two different schedules of everolimus to see how well they work in treating patients with recurrent or metastatic breast cancer.

Description:

OBJECTIVES:

Primary

• Determine the efficacy of 2 different treatment schedules of everolimus, in terms of clinical/radiological response and early progression, in patients with recurrent or metastatic breast cancer.

Secondary

• Determine the time to progression and response duration in patients treated with these regimens.

• Determine the toxic effects of these regimens in these patients.

• Correlate molecular markers of mTOR activity in tumor tissue with objective tumor response in patients treated with these regimens.

OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified according to presence of visceral metastases (yes vs no) and prior chemotherapy regimens for recurrent disease (0 vs 1). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral everolimus once daily on days 1-28.

• Arm II: Patients receive oral everolimus on days 1, 8, 15, and 22. In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 4 weeks and then periodically until disease progression.

PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: January 18, 2011
• Est. primary completion date: July 22, 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed breast cancer

• Metastatic or recurrent disease

• Considered incurable

• Measurable disease, defined as = 1 unidimensionally measurable lesion = 20 mm by conventional techniques or = 10 mm by spiral CT scan

• Two primary breast cancers allowed

• Paraffin-embedded primary or metastatic tumor sample available

• No known brain metastases

• Hormone receptor status:

• Not specified

PATIENT CHARACTERISTICS:

Sex

• Male or female

Menopausal status

• Not specified

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Absolute granulocyte count = 1,500/mm^3

• Platelet count = 100,000/mm^3

Hepatic

• Bilirubin = 1.5 times upper limit of normal (ULN)

• AST and ALT = 2.5 times ULN

Renal

• Creatinine = 1.5 times ULN

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No active uncontrolled infection

• No upper gastrointestinal condition or other condition that would preclude ability to take oral medication

• No other serious medical condition that would preclude study participation

• No psychiatric illness or neurologic disorder that would preclude study compliance

• No other malignancy within the past 5 years except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix or bladder

PRIOR CONCURRENT THERAPY:

Chemotherapy

• At least 4 weeks since prior chemotherapy

• Prior adjuvant chemotherapy allowed

• No more than 1 prior chemotherapy regimen for metastatic or recurrent disease

Endocrine therapy

• At least 5 days since prior hormonal therapy

Radiotherapy

• At least 4 weeks since prior radiotherapy except for low-dose, limited-fraction, palliative, nonmyelosuppressive radiotherapy, defined as radiotherapy to < 20% of functioning bone marrow

• If prior radiotherapy was to sole site of disease, must have subsequent documented disease progression at that site

Surgery

• At least 3 weeks since prior major surgery

Other

• Concurrent prophylactic bisphosphonates allowed, if started prior to study entry

• No concurrent potent inhibitors of cytochrome 3A4, such as erythromycin, diltiazem, or ketoconazole and similar antifungals

• No other concurrent anticancer therapy

• No other concurrent investigational agents

• No concurrent grapefruit juice

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• everolimus

Locations

Country	Name	City	State
Canada	Margaret and Charles Juravinski Cancer Centre	Hamilton	Ontario
Canada	British Columbia Cancer Agency - Centre for the Southern Interior	Kelowna	British Columbia
Canada	Fraser Valley Cancer Centre at British Columbia Cancer Agency	Surrey	British Columbia
Canada	Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre	Toronto	Ontario
Canada	British Columbia Cancer Agency - Vancouver Cancer Centre	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
NCIC Clinical Trials Group

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in p — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate by clinical evaluation every 4 weeks and radiologic reevaluation every 8 weeks
Primary	Early progression rate by clinical evaluation every 4 weeks and radiologic reevaluation every 8 weeks
Secondary	Adverse event rates
Secondary	Time to progression by clinical evaluation every 4 weeks and radiologic reevaluation every 8 weeks
Secondary	Response duration by evaluation 4 weeks after response and then every 8 weeks
Secondary	Correlative assessment of response with molecular markers of mTor activity on archival tissue
Secondary	Optional correlative assessment of response with molecular markers of mTor activity on fresh tissue